Nasdaq

Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy

CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...
Yahoo Finance

Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity

– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Engineered exosomes with directed cellular ...
Nasdaq

New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

Data at ASGCT 2021 show ability to design exosomes with specific features for immune evasion, tunable vaccine development, targeted cell tropism and potent target engagement CAMBRIDGE, Mass., May 11, ...
Business Wire

Codiak Presents New Preclinical Data Demonstrating Potential of EngEx™ Engineered Exosomes to Drive New Class of Molecular Medicines

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical data on ...
EurekAlert!

Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances

CAMBRIDGE, Mass., February 18, 2022 — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of ...